---
title: 2.Insurance risks 
description: 
---
# 2.Insurance risks

## 2.1	Life insurance risks
### 2.1.1	Definition

<G2Col>
<div>

  7. Life risk charges are applicable to life business and similar to life health business and consist of the following five sub-risk charges.
  - a.	Mortality risk: risk of losses due to actual mortality rates higher than expected;
  - b.	Longevity risk: risk of losses due to actual mortality rates lower than expected;
  - c.	Morbidity/Disability risk: risk of losses due to unexpected changes in the level, trend or volatility of disability, sickness and morbidity rates;
  - d.	Lapse risk: risk of losses due to unexpected changes in the level or volatility of rates of policy lapses, terminations, renewals and surrenders;
  - e.	Expense risk: risk of losses due to unexpected changes in the incidence of expense incurred.
</div>
<div>
  7. ìƒëª…ë³´í—˜ ë¦¬ìŠ¤í¬ ê³„ìˆ˜ëŠ” ìƒëª…ë³´í—˜ ë° ìƒëª…Â·ê±´ê°•ë³´í—˜ì— ì ìš©ë˜ë©°, ë‹¤ìŒ 5ê°€ì§€ í•˜ìœ„ ë¦¬ìŠ¤í¬ë¡œ êµ¬ì„±ë¨.
  - a. ì‚¬ë§ ìœ„í—˜(Mortality Risk): ì‹¤ì œ ì‚¬ë§ë¥ ì´ ì˜ˆìƒë³´ë‹¤ ë†’ì•„ì§ˆ ìœ„í—˜
  - b. ì¥ìˆ˜ ìœ„í—˜(Longevity Risk): ì‹¤ì œ ì‚¬ë§ë¥ ì´ ì˜ˆìƒë³´ë‹¤ ë‚®ì•„ì§ˆ ìœ„í—˜
  - c. ì§ˆë³‘/ì¥ì•  ìœ„í—˜(Morbidity/Disability Risk): ì¥ì• Â·ì§ˆë³‘Â·ìœ ë³‘ë¥  ìˆ˜ì¤€, ì¶”ì„¸, ë³€ë™ì„±ì´ ì˜ˆìƒê³¼ ë‹¤ë¥´ê²Œ ë³€í™”í•  ìœ„í—˜
  - d. í•´ì§€ ìœ„í—˜(Lapse Risk): ê³„ì•½ í•´ì§€, ì¢…ë£Œ, ê°±ì‹ , í•´ì•½ ë¹„ìœ¨ì´ ì˜ˆìƒê³¼ ë‹¤ë¥´ê²Œ ë³€í™”í•  ìœ„í—˜
  - e. ì‚¬ì—…ë¹„ ìœ„í—˜(Expense Risk): ë°œìƒ ë¹„ìš©ì´ ì˜ˆìƒê³¼ ë‹¤ë¥´ê²Œ ë³€í™”í•  ìœ„í—˜
</div>
</G2Col>

### 2.1.2	ICS Methodology

<G2Col>
<div>
  8. For each of the five sub-risks listed above, stress factors are applied to the parameters underpinning the calculation of current estimates, in order to generate stressed balance sheets in line with the ICS target criteria â€“ a probability of occurrence of 0.5% over a 1-year time horizon.
</div>
<div>
  8. ìœ„ 5ê°€ì§€ í•˜ìœ„ ë¦¬ìŠ¤í¬ë³„ë¡œ, í˜„ì¬ ì¶”ì •ì¹˜ë¥¼ ì‚°ì¶œí•˜ëŠ” ì£¼ìš” ë³€ìˆ˜ë¥¼ ëŒ€ìƒìœ¼ë¡œ ìŠ¤íŠ¸ë ˆìŠ¤ ê³„ìˆ˜ë¥¼ ì ìš©í•¨.
  - â€¢ ICS ê¸°ì¤€ì— ë”°ë¼, 1ë…„ ê¸°ê°„ ë‚´ 0.5% í™•ë¥ ë¡œ ë°œìƒí•  ìˆ˜ì¤€ì˜ ìŠ¤íŠ¸ë ˆìŠ¤ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ë°˜ì˜í•˜ì—¬ ì¬ë¬´ì œí‘œë¥¼ ì‚°ì¶œí•¨.
</div>
</G2Col>

<G2Col>
<div>
  9. The calculation of all sub-risk charges are based on the following geographical segmentation, with respect to the location where risks are written:
  - a.	EEA and Switzerland;
  - b.	US and Canada;
  - c.	China;
  - d.	Japan;
  - e.	Other developed markets; and
  - f.	Other emerging markets.
</div>
<div>
  9. ëª¨ë“  í•˜ìœ„ ë¦¬ìŠ¤í¬ ê³„ìˆ˜ëŠ” ë³´í—˜ ë¦¬ìŠ¤í¬ ì¸ìˆ˜ ì§€ì—­ì„ ê¸°ì¤€ìœ¼ë¡œ ë‹¤ìŒê³¼ ê°™ì´ ë¶„ë¥˜í•˜ì—¬ ì‚°ì¶œí•¨.
  - a. EEA ë° ìŠ¤ìœ„ìŠ¤
  - b. ë¯¸êµ­ ë° ìºë‚˜ë‹¤
  - c. ì¤‘êµ­
  - d. ì¼ë³¸
  - e. ê¸°íƒ€ ì„ ì§„ì‹œì¥
  - f. ê¸°íƒ€ ì‹ í¥ì‹œì¥
</div>
</G2Col>

<G2Col>
<div>
  10. The five Life insurance sub-risks charges are aggregated with a correlation matrix; the correlation factors are based on expert judgement whether the corelation between two sub-risks is negative, negligible, low, medium or high.
</div>
<div>
  10. 5ê°€ì§€ ìƒëª…ë³´í—˜ í•˜ìœ„ ë¦¬ìŠ¤í¬ ê³„ìˆ˜ëŠ” ìƒê´€ í–‰ë ¬(correlation matrix)ì„ í†µí•´ ì§‘ê³„í•¨.
   - â€¢ ê° í•˜ìœ„ ë¦¬ìŠ¤í¬ ê°„ ìƒê´€ê´€ê³„ëŠ” ì „ë¬¸ê°€ íŒë‹¨ì— ë”°ë¼ ìŒ(-), ë¯¸ë¯¸, ë‚®ìŒ, ì¤‘ê°„, ë†’ìŒ ë“±ìœ¼ë¡œ êµ¬ë¶„ë¨.
</div>
</G2Col>

<G2Col>
<div>
  11. For each of the five sub-risks, the risk charge is calculated both with and without the impact of management actions.
</div>
<div>
  11. ê° í•˜ìœ„ ë¦¬ìŠ¤í¬ë³„ë¡œ, ê´€ë¦¬ ì¡°ì¹˜(Management Actions) ë°˜ì˜ ì—¬ë¶€ì— ë”°ë¼ ìœ„í—˜ ê³„ìˆ˜ë¥¼ ë³„ë„ë¡œ ì‚°ì¶œí•¨.
</div>
</G2Col>

<G2Col>
<div>
  12. The design of Life risks was informed by Field Testing exercises from 2014 to 2019, confidential reporting exercises from 2020 to 2024, as well as public consultations on ICS in 2014, 2016 and 2018. The calibration of Life risks was supported by targeted data collections in 2016, 2018 2019 and 2022 (all risks), as well as 2015 and 2017 (Morbidity/disability risk).
</div>
<div>
 12. ìƒëª…ë³´í—˜ ë¦¬ìŠ¤í¬ëŠ” 2014\~2019ë…„ í•„ë“œ í…ŒìŠ¤íŠ¸, 2020\~2024ë…„ ë¹„ê³µê°œ ë³´ê³ , 2014Â·2016Â·2018ë…„ ICS ê³µê°œ í˜‘ì˜ ë‚´ìš©ì„ ë°˜ì˜í•˜ì—¬ ì„¤ê³„ë¨.
 - â€¢ 2016Â·2018Â·2019Â·2022ë…„(ì „ ë¦¬ìŠ¤í¬ ëŒ€ìƒ), 2015Â·2017ë…„(ì§ˆë³‘/ì¥ì•  ìœ„í—˜ ëŒ€ìƒ) ë°ì´í„° ìˆ˜ì§‘ì„ í†µí•´ ìœ„í—˜ ê³„ìˆ˜ ì‚°ì¶œì„ ì§€ì›í•¨.
</div>
</G2Col>

### 2.1.3	Calibration of risks

<G2Col>
<div>
  13. To inform the calibration of Life risks, supplementary data collections were run in 2018, 2019 and 2022, together with the Field Testing / confidential reporting data collections. In the context of those supplementary Life data collections, Volunteer Groups were requested to provide data covering at least 10 consecutive years (in 2018 and 2019), and 13 consecutive years (in 2022).
</div>
<div>
  13. ìƒëª…ë³´í—˜ ë¦¬ìŠ¤í¬ ë°ì´í„°ì˜ ì¶”ê°€ì ì¸ ìˆ˜ì§‘ì€ 2018Â·2019Â·2022ë…„ì— í•„ë“œ í…ŒìŠ¤íŠ¸/ë¹„ê³µê°œ ë³´ê³ ì™€ í•¨ê»˜ ì§„í–‰ë¨.
  - â€¢ í•´ë‹¹ ë°ì´í„° ìˆ˜ì§‘ì—ì„œ ìë°œì  ì°¸ì—¬ ê·¸ë£¹(Volunteer Groups)ì€ ìµœì†Œ 10ë…„(2018Â·2019ë…„), 13ë…„(2022ë…„)ì˜ ì—°ì† ë°ì´í„°ë¥¼ ì œê³µí•¨.
</div>
</G2Col>
 

#### 2.1.3.1	Mortality risk

<G2Col>
<div>
  14. The calculation of the mortality risk charge is based on a scenario of general permanent increase in mortality rates.
</div>
<div>
 14. ì‚¬ë§ ìœ„í—˜ ê³„ìˆ˜ëŠ” ì‚¬ë§ë¥ ì˜ ì „ë°˜ì ì¸ ì˜êµ¬ ì¦ê°€ë¥¼ ê°€ì •í•œ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì‚°ì¶œë¨.
</div>
</G2Col>

<G2Col>
<div>
	15. Based on a review of existing risk-based supervisory frameworks, and after field testing different factors between 10% and 15%, the stress factor was provisionally set at 12.5% for all regions.
</div>
<div>
 15. ê¸°ì¡´ ë¦¬ìŠ¤í¬ ê¸°ë°˜ ê°ë… ì²´ê³„ë¥¼ ê²€í† í•˜ê³ , 10~15% ìˆ˜ì¤€ì—ì„œ ë‹¤ì–‘í•œ ìš”ì¸ì„ í•„ë“œ í…ŒìŠ¤íŠ¸í•œ í›„ ìŠ¤íŠ¸ë ˆìŠ¤ ê³„ìˆ˜ë¥¼ 12.5%ë¡œ ì„¤ì •í•¨.
</div>
</G2Col>

###### 16
<G2Col>
<div>
  16. In 2018 and 2019, data were collected from IAIGs in order to inform a potential refinement of the calibration. Based on those data and on the assumption that the variable <GTooltip label="ğ´/ğ¸ âˆ’ 1" desc="(where ğ´ and ğ¸ respectively denote actual and expected claims, due to all causes, incurred in each financial year)"/> follows a normal distribution (for which observations are independent and identically distributed), the following 99.5th percentiles<GTooltipIcon desc="In practice, the 99.5th percentiles were determined as 2.58 times the historical standard deviation calculated for the ğ´/ğ¸ âˆ’ 1 variable."/> were calculated for mortality rates:
    - a. 6% for business written in Japan;
    - b. 15% for business written in China; and
    - c. 10% for business written in other developed markets.
</div>
<div>
 16. 2018Â·2019ë…„ IAIG ë°ì´í„° ìˆ˜ì§‘í•˜ì—¬ ìœ„í—˜ê³„ìˆ˜ ì‚°ì¶œë°©ì‹ì˜ ë³´ì™„ ê°€ëŠ¥ì„±ì„ ê²€í† í•¨. ì‹¤ì œ <GTooltip label="ì²­êµ¬ì•¡" desc="(ëª¨ë“  ì›ì¸ìœ¼ë¡œ ì¸í•´ ê° íšŒê³„ì—°ë„ì— ë°œìƒí•œ ì²­êµ¬ì•¡ì„ ê¸°ì¤€)"/>(ğ´) ê³¼ ì˜ˆìƒ ì²­êµ¬ì•¡(ğ¸) ê°„ ì°¨ì´(ğ´/ğ¸ âˆ’ 1) ë³€ìˆ˜ê°€ ì •ê·œë¶„í¬ë¥¼ ë”°ë¥´ë©°, ê´€ì¸¡ê°’ì´ ë…ë¦½ì ì´ê³  ë™ì¼í•˜ê²Œ ë¶„í¬í•œë‹¤ê³  ê°€ì •í•˜ê³ , 99.5% ë¶„ìœ„ìˆ˜<GTooltipIcon desc="99.5% ë¶„ìœ„ìˆ˜ëŠ” ğ´/ğ¸ âˆ’ 1 ë³€ìˆ˜ì˜ í‘œì¤€í¸ì°¨ì— 2.58ë°°ë¥¼ ì ìš©í•˜ì—¬ ì‚°ì¶œí•¨."/>ë¥¼ ì‚°ì¶œí•¨.
   - a. ì¼ë³¸: 6%
   - b. ì¤‘êµ­: 15%
   - c. ê¸°íƒ€ ì„ ì§„ì‹œì¥: 10%
</div>
</G2Col>

<G2Col>
<div>
  17. Data for the Japanese market were considered sufficient evidence, with over 10 years of history; therefore, it was decided to set the stress factor for business written in Japan to 10% (including a prudence margin based on expert judgement). The appropriateness of that level was confirmed by data collected in 2022.
</div>
<div>
  17. ì¼ë³¸ ì‹œì¥ì˜ ê²½ìš°, 10ë…„ ì´ìƒì˜ ë°ì´í„°ê°€ í™•ë³´ë˜ì—ˆìœ¼ë¯€ë¡œ ì‚¬ë§ ìœ„í—˜ ê³„ìˆ˜ë¥¼ 10%(ì „ë¬¸ê°€ íŒë‹¨ ê¸°ë°˜ ì¶”ê°€ ì‹ ì¤‘ì„± ë°˜ì˜)ë¡œ ì„¤ì •í•¨.
   - â€¢ 2022ë…„ ë°ì´í„° ìˆ˜ì§‘ì—ì„œë„ ì ì •ì„±ì´ í™•ì¸ë¨.
</div>
</G2Col>

<G2Col>
<div>
  18. For business written in China, the 2019 and 2022 data collections provided evidence of a risk factor between 13% and 27%; the risk factor was therefore set to 15%.
</div>
<div>
  18. ì¤‘êµ­ ì‹œì¥ì˜ ê²½ìš°, 2019Â·2022ë…„ ë°ì´í„°ì—ì„œ ìœ„í—˜ ê³„ìˆ˜ê°€ 13\~27% ë²”ìœ„ë¡œ ê´€ì¸¡ë¨.
   - â€¢ ì´ì— ë”°ë¼, ìµœì¢… ìœ„í—˜ ê³„ìˆ˜ë¥¼ 15%ë¡œ ì„¤ì •í•¨.
</div>
</G2Col>

<G2Col>
<div>
  19. For other developed markets, data collected in 2022 supported a 12.5% risk factor.
</div>
<div>
  19. ê¸°íƒ€ ì„ ì§„ì‹œì¥ì˜ ê²½ìš°, 2022ë…„ ë°ì´í„°ë¥¼ ê¸°ë°˜ìœ¼ë¡œ 12.5% ìˆ˜ì¤€ì˜ ìœ„í—˜ ê³„ìˆ˜ê°€ ì‚°ì¶œë¨.
</div>
</G2Col>

<G2Col>
<div>
  20. For US and Canada and other emerging markets, the lack of historical data provided in all data collections did not allow for an adjustment of the calibration. Therefore, based on expert judgement the stress factor was aligned with other developed markets (12.5%).
</div>
<div>
  20. ë¯¸êµ­Â·ìºë‚˜ë‹¤ ë° ê¸°íƒ€ ì‹ í¥ì‹œì¥ì˜ ê²½ìš°, ê³¼ê±° ë°ì´í„° ë¶€ì¡±ìœ¼ë¡œ ì¸í•´ ìœ„í—˜ ê³„ìˆ˜ ì‚°ì¶œì´ ì–´ë ¤ì›€.
   - â€¢ ì „ë¬¸ê°€ íŒë‹¨ì„ ë°”íƒ•ìœ¼ë¡œ, í•´ë‹¹ ì‹œì¥ì˜ ìŠ¤íŠ¸ë ˆìŠ¤ ê³„ìˆ˜ë¥¼ ê¸°íƒ€ ì„ ì§„ì‹œì¥ê³¼ ë™ì¼í•œ 12.5%ë¡œ ì„¤ì •í•¨.
</div>
</G2Col>

<G2Col>
<div>
  21. For EEA and Switzerland, 10 years of historical data collected through the 2019 data collection showed that a 12.5% risk factor was appropriate. Data collected in 2022 continue to support this conclusion.
</div>
<div>
  21. EEA ë° ìŠ¤ìœ„ìŠ¤ ì‹œì¥ì˜ ê²½ìš°, 2019ë…„ ë°ì´í„°(10ë…„ ì´ìƒ ê´€ì¸¡ì¹˜)ê°€ 12.5% ìœ„í—˜ ê³„ìˆ˜ë¥¼ ì ì ˆí•œ ìˆ˜ì¤€ìœ¼ë¡œ ì œì‹œí•¨.
   - â€¢ 2022ë…„ ë°ì´í„°ì—ì„œë„ í•´ë‹¹ ê²°ë¡ ì´ ìœ ì§€ë¨.
</div>
</G2Col>



#### 2.1.3.2	Longevity risk

<G2Col>
<div>
  22. The calculation of the longevity risk charge is based on a scenario of a permanent decrease in mortality rates.
</div>
<div>
  22. ì¥ìˆ˜ ìœ„í—˜ ê³„ìˆ˜ëŠ” ì‚¬ë§ë¥ ì˜ ì˜êµ¬ì  ê°ì†Œë¥¼ ê°€ì •í•œ ì‹œë‚˜ë¦¬ì˜¤ë¥¼ ê¸°ë°˜ìœ¼ë¡œ ì‚°ì¶œë¨.
</div>
</G2Col>


<G2Col>
<div>
  23. Based on results of data provided by IAIGs for the calibration exercise in 2016, a stress factor of 17.5% across all regions was specified<GTooltipIcon desc="The stress factor was chosen in a way to cover implicitly the trend and volatility components of the longevity risk, since the choice was made not to include explicitly those components in the design. This approach was considered striking an appropriate balance between complexity and risk sensitivity."/> for the 2017 Field Testing. In the absence of any evidence that this level of stress is inappropriate, the 17.5% factor has remained unchanged since then.
</div>
<div>
  23. 2016ë…„ IAIG ë°ì´í„° ìˆ˜ì§‘ ê²°ê³¼ë¥¼ ë°”íƒ•ìœ¼ë¡œ, 2017ë…„ í•„ë“œ í…ŒìŠ¤íŠ¸ì—ì„œ ëª¨ë“  ì§€ì—­ì— ëŒ€í•´ 17.5% ìŠ¤íŠ¸ë ˆìŠ¤ ê³„ìˆ˜ë¥¼ ì ìš©í•¨.<GTooltipIcon desc="ìŠ¤íŠ¸ë ˆìŠ¤ ê³„ìˆ˜ëŠ” ì¥ìˆ˜ ìœ„í—˜ì˜ ì¶”ì„¸ ë° ë³€ë™ì„± ìš”ì†Œë¥¼ ëª…ì‹œì ìœ¼ë¡œ í¬í•¨í•˜ì§€ ì•ŠëŠ” ë°©ì‹ìœ¼ë¡œ ì„¤ê³„ë˜ì—ˆìœ¼ë©°, ëŒ€ì‹  ì´ëŸ¬í•œ ìš”ì†Œë¥¼ ì•”ë¬µì ìœ¼ë¡œ ë°˜ì˜í•˜ë„ë¡ ì„ ì •ë¨. ì´ëŸ¬í•œ ì ‘ê·¼ ë°©ì‹ì€ ë³µì¡ì„±ê³¼ ìœ„í—˜ ë¯¼ê°ë„ ê°„ì˜ ê· í˜•ì„ ì ì ˆíˆ ìœ ì§€í•˜ëŠ” ê²ƒìœ¼ë¡œ í‰ê°€ë¨."/>
  - â€¢ í•´ë‹¹ ìˆ˜ì¤€ì´ ë¶€ì ì ˆí•˜ë‹¤ëŠ” ê·¼ê±°ê°€ ì—†ì—ˆìœ¼ë¯€ë¡œ, ì´í›„ ë³€ê²½ ì—†ì´ ìœ ì§€ë¨.
</div>
</G2Col>

#### 2.1.3.3	Morbidity and Disability risk


<G2Col>
<div>
  24. For the calculation of the morbidity/disability risk charge, the business is split:
  - a.	By type of guarantee:
    - i.	Medical expenses (Category 1)
    - ii.	Lump sum in case of a health event (Category 2)
    - iii.	Short-term recurring payments (Category 3)
    - iv.	Long-term recurring payments (Category 4)
  - b.	By term of contract:
    - i.	Short-term (up to 5 years)
    - ii.	Long-term (more than 5 years)

  resulting in eight segments (4 types of guarantee and for each type, 2 terms of contract).
</div>
<div>
  24. ì§ˆë³‘/ì¥ì•  ìœ„í—˜ ê³„ìˆ˜ ì‚°ì¶œ ì‹œ, ì‚¬ì—…ì„ ë‹¤ìŒ ê¸°ì¤€ìœ¼ë¡œ êµ¬ë¶„í•¨. ì´ 8ê°œ ì„¸ê·¸ë¨¼íŠ¸ë¡œ ë¶„ë¥˜(4ê°œ ë³´ì¥ ìœ í˜• Ã— 2ê°œ ê³„ì•½ ê¸°ê°„ë³„ êµ¬ë¶„).
  - a. ë³´ì¥ ìœ í˜•ë³„ êµ¬ë¶„
    - i. ì˜ë£Œë¹„ ë³´ì¥ (Category 1)
    - ii. íŠ¹ì • ê±´ê°• ì‚¬ê±´ ë°œìƒ ì‹œ ì¼ì‹œê¸ˆ ì§€ê¸‰ (Category 2)
    - iii. ë‹¨ê¸° ë¶„í•  ì§€ê¸‰ (Category 3)
    - iv. ì¥ê¸° ë¶„í•  ì§€ê¸‰ (Category 4)
  - b. ê³„ì•½ ê¸°ê°„ë³„ êµ¬ë¶„
    - i. ë‹¨ê¸°(5ë…„ ì´í•˜)
    - ii. ì¥ê¸°(5ë…„ ì´ˆê³¼)
</div>
</G2Col>
